Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5531273 | Cytotherapy | 2017 | 10 Pages |
Abstract
The use of bioreactors in cell therapy applications is on the rise, as clinical trials and commercialization of cell therapy-based products are moving to the forefront of treatment opportunities. This review focuses on the considerations and benefits of using bioreactors for cell therapy manufacturing, with an emphasis on autologous versus allogenic, scalability, tissue engineering, automation and comparability and consistency in the final product. Evaluation and choice of the right bioreactor for any given process and indication is paramount when moving into scalable platforms and processes that can support the cell therapy industry's needs.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cell Biology
Authors
Shannon Eaker, Eytan Abraham, Julie Allickson, Thomas A. Brieva, Dolores Baksh, Thomas R.J. Heathman, Biren Mistry, Nan Zhang,